IND Swift Laboratories Ltd
NSE:INDSWFTLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IND Swift Laboratories Ltd
Net Income (Common)
IND Swift Laboratories Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IND Swift Laboratories Ltd
NSE:INDSWFTLAB
|
Net Income (Common)
₹2.8B
|
CAGR 3-Years
190%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
11%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹45.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹109.2B
|
CAGR 3-Years
37%
|
CAGR 5-Years
35%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Income (Common)
₹46.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹22.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
IND Swift Laboratories Ltd
Glance View
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm operates through the bulk drugs and pharmaceuticals segment. Its business includes Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The firm has a product portfolio of approximately 12 therapeutic segments. The company is manufacturing APIs of complex therapies namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Multidisciplinary skills Synthetic Medicinal Chemistry Custom Synthesis Process R&D cGMP Manufacturing Analytical Development Regulatory Support Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. The Company’s products and services include API products, custom chemicals, and impurities. The firm manufacturing facilities are at Derabassi and Jammu Kashmir.
See Also
What is IND Swift Laboratories Ltd's Net Income (Common)?
Net Income (Common)
2.8B
INR
Based on the financial report for Dec 31, 2025, IND Swift Laboratories Ltd's Net Income (Common) amounts to 2.8B INR.
What is IND Swift Laboratories Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
46%
Over the last year, the Net Income (Common) growth was -22%. The average annual Net Income (Common) growth rates for IND Swift Laboratories Ltd have been 190% over the past three years , 46% over the past five years .
